Sex differences in prolactin levels and clinical outcomes in patients with a first psychotic episode
To analyze the clinical, neurocognitive, and functional impact of prolactin levels according to sex in patients with a First Episode Psychosis (FEP). We measured prolactin levels in 221 non-affective FEP patients treated with antipsychotics (AP) and 224 healthy controls, at baseline and 2-year follo...
Gespeichert in:
| Veröffentlicht in: | Psychoneuroendocrinology 2024-11, Vol.169, p.107112, Article 107112 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 107112 |
| container_title | Psychoneuroendocrinology |
| container_volume | 169 |
| creator | Jordà-Baleri, Teresa Garriga, Marina Mezquida, Gisela Cuesta, Manuel J. Martinez-Aran, Anabel Garcia-Rizo, Clemente Lobo, Antonio González-Pinto, Ana Diaz-Caneja, Covadonga M. Roldán, Alexandra Vieta, Eduard Baeza, Inmaculada Trabsa, Amira Montalvo, Itziar Tortorella, Alfonso Menculini, Giulia Verdolini, Norma Ramos-Quiroga, Josep Antoni Sánchez Torres, Ana M. Bernardo, Miquel Amoretti, Silvia |
| description | To analyze the clinical, neurocognitive, and functional impact of prolactin levels according to sex in patients with a First Episode Psychosis (FEP).
We measured prolactin levels in 221 non-affective FEP patients treated with antipsychotics (AP) and 224 healthy controls, at baseline and 2-year follow-up. We examined whether the relationships between clinical and functional variables were mediated by prolactin, controlling for antipsychotic use, according to sex.
Prolactin levels were higher in patients when compared to controls at both time points. Baseline factors associated with prolactin were chlorpromazine equivalents, attention, and executive functioning. In the FEP group, prolactin levels were associated with functioning and diminished expression in males, and with working memory in females. Prolactin levels (p=0.0134) played a role as a mediator between negative symptomatology (p=0.086) and functional outcome (p=0.008) only in FEP male patients at baseline.
Prolactin plays a role in the functionality and clinical symptomatology of FEP patients. Our results suggest that pharmacological counselling in patients with hyperprolactinemia at baseline and negative symptomatology might improve their functional and clinical outcomes.
•Prolactin plays a role in the functionality and clinical symptomatology of patients.•Prolactin levels mediated negative symptomatology and functional outcomes in males.•Prolactin was associated with functioning and diminished expression in males.•Prolactin was associated with working memory in females. |
| doi_str_mv | 10.1016/j.psyneuen.2024.107112 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3089878321</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0306453024001562</els_id><sourcerecordid>3089878321</sourcerecordid><originalsourceid>FETCH-LOGICAL-c245t-369f11305f51acf2836c9832a41cc8838642046761d56d64365464d8a3d92b4c3</originalsourceid><addsrcrecordid>eNqFkMlOwzAQQC0EgrL8AvKRS4q3uM4NhNgkJA7A2XLHE9VVmhTbYfl7XLVw5TSj0ZvtEXLO2ZQzri-X03X67nHEfiqYUKU441zskQk3M1lJqdk-mTDJdKVqyY7IcUpLxpg2WhySI9lwpmsjJsS_4Bf1oW0xYg-YaOjpOg6dg1yyDj-wS9T1nkIX-gCuo8OYYVjtSJcD9jnRz5AX1NE2xJRpuQwWQw5AcR3S4PGUHLSuS3i2iyfk7e729eahenq-f7y5fqpAqDpXUjct55LVbc0dtMJIDY2RwikOYIw0Wgmm9ExzX2uvldS10sobJ30j5grkCbnYzi0fvI-Ysl2FBNh1rsdhTFYy05hZmcgLqrcoxCGliK1dx7By8dtyZjeG7dL-GrYbw3ZruDSe73aM8xX6v7ZfpQW42gLFHH4EjDZB2Lj1ISJk64fw344fKSKQKQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3089878321</pqid></control><display><type>article</type><title>Sex differences in prolactin levels and clinical outcomes in patients with a first psychotic episode</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Jordà-Baleri, Teresa ; Garriga, Marina ; Mezquida, Gisela ; Cuesta, Manuel J. ; Martinez-Aran, Anabel ; Garcia-Rizo, Clemente ; Lobo, Antonio ; González-Pinto, Ana ; Diaz-Caneja, Covadonga M. ; Roldán, Alexandra ; Vieta, Eduard ; Baeza, Inmaculada ; Trabsa, Amira ; Montalvo, Itziar ; Tortorella, Alfonso ; Menculini, Giulia ; Verdolini, Norma ; Ramos-Quiroga, Josep Antoni ; Sánchez Torres, Ana M. ; Bernardo, Miquel ; Amoretti, Silvia</creator><creatorcontrib>Jordà-Baleri, Teresa ; Garriga, Marina ; Mezquida, Gisela ; Cuesta, Manuel J. ; Martinez-Aran, Anabel ; Garcia-Rizo, Clemente ; Lobo, Antonio ; González-Pinto, Ana ; Diaz-Caneja, Covadonga M. ; Roldán, Alexandra ; Vieta, Eduard ; Baeza, Inmaculada ; Trabsa, Amira ; Montalvo, Itziar ; Tortorella, Alfonso ; Menculini, Giulia ; Verdolini, Norma ; Ramos-Quiroga, Josep Antoni ; Sánchez Torres, Ana M. ; Bernardo, Miquel ; Amoretti, Silvia ; PEPs Group</creatorcontrib><description>To analyze the clinical, neurocognitive, and functional impact of prolactin levels according to sex in patients with a First Episode Psychosis (FEP).
We measured prolactin levels in 221 non-affective FEP patients treated with antipsychotics (AP) and 224 healthy controls, at baseline and 2-year follow-up. We examined whether the relationships between clinical and functional variables were mediated by prolactin, controlling for antipsychotic use, according to sex.
Prolactin levels were higher in patients when compared to controls at both time points. Baseline factors associated with prolactin were chlorpromazine equivalents, attention, and executive functioning. In the FEP group, prolactin levels were associated with functioning and diminished expression in males, and with working memory in females. Prolactin levels (p=0.0134) played a role as a mediator between negative symptomatology (p=0.086) and functional outcome (p=0.008) only in FEP male patients at baseline.
Prolactin plays a role in the functionality and clinical symptomatology of FEP patients. Our results suggest that pharmacological counselling in patients with hyperprolactinemia at baseline and negative symptomatology might improve their functional and clinical outcomes.
•Prolactin plays a role in the functionality and clinical symptomatology of patients.•Prolactin levels mediated negative symptomatology and functional outcomes in males.•Prolactin was associated with functioning and diminished expression in males.•Prolactin was associated with working memory in females.</description><identifier>ISSN: 0306-4530</identifier><identifier>ISSN: 1873-3360</identifier><identifier>EISSN: 1873-3360</identifier><identifier>DOI: 10.1016/j.psyneuen.2024.107112</identifier><identifier>PMID: 39106582</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Antipsychotic Agents - therapeutic use ; Female ; First-episode psychosis ; Functioning ; Humans ; Hyperprolactinemia - blood ; Male ; Negative symptoms ; Prolactin ; Prolactin - blood ; Psychotic Disorders - blood ; Psychotic Disorders - drug therapy ; Sex Characteristics ; Sex Factors ; Treatment Outcome ; Young Adult</subject><ispartof>Psychoneuroendocrinology, 2024-11, Vol.169, p.107112, Article 107112</ispartof><rights>2024 Elsevier Ltd</rights><rights>Copyright © 2024 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c245t-369f11305f51acf2836c9832a41cc8838642046761d56d64365464d8a3d92b4c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0306453024001562$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39106582$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jordà-Baleri, Teresa</creatorcontrib><creatorcontrib>Garriga, Marina</creatorcontrib><creatorcontrib>Mezquida, Gisela</creatorcontrib><creatorcontrib>Cuesta, Manuel J.</creatorcontrib><creatorcontrib>Martinez-Aran, Anabel</creatorcontrib><creatorcontrib>Garcia-Rizo, Clemente</creatorcontrib><creatorcontrib>Lobo, Antonio</creatorcontrib><creatorcontrib>González-Pinto, Ana</creatorcontrib><creatorcontrib>Diaz-Caneja, Covadonga M.</creatorcontrib><creatorcontrib>Roldán, Alexandra</creatorcontrib><creatorcontrib>Vieta, Eduard</creatorcontrib><creatorcontrib>Baeza, Inmaculada</creatorcontrib><creatorcontrib>Trabsa, Amira</creatorcontrib><creatorcontrib>Montalvo, Itziar</creatorcontrib><creatorcontrib>Tortorella, Alfonso</creatorcontrib><creatorcontrib>Menculini, Giulia</creatorcontrib><creatorcontrib>Verdolini, Norma</creatorcontrib><creatorcontrib>Ramos-Quiroga, Josep Antoni</creatorcontrib><creatorcontrib>Sánchez Torres, Ana M.</creatorcontrib><creatorcontrib>Bernardo, Miquel</creatorcontrib><creatorcontrib>Amoretti, Silvia</creatorcontrib><creatorcontrib>PEPs Group</creatorcontrib><title>Sex differences in prolactin levels and clinical outcomes in patients with a first psychotic episode</title><title>Psychoneuroendocrinology</title><addtitle>Psychoneuroendocrinology</addtitle><description>To analyze the clinical, neurocognitive, and functional impact of prolactin levels according to sex in patients with a First Episode Psychosis (FEP).
We measured prolactin levels in 221 non-affective FEP patients treated with antipsychotics (AP) and 224 healthy controls, at baseline and 2-year follow-up. We examined whether the relationships between clinical and functional variables were mediated by prolactin, controlling for antipsychotic use, according to sex.
Prolactin levels were higher in patients when compared to controls at both time points. Baseline factors associated with prolactin were chlorpromazine equivalents, attention, and executive functioning. In the FEP group, prolactin levels were associated with functioning and diminished expression in males, and with working memory in females. Prolactin levels (p=0.0134) played a role as a mediator between negative symptomatology (p=0.086) and functional outcome (p=0.008) only in FEP male patients at baseline.
Prolactin plays a role in the functionality and clinical symptomatology of FEP patients. Our results suggest that pharmacological counselling in patients with hyperprolactinemia at baseline and negative symptomatology might improve their functional and clinical outcomes.
•Prolactin plays a role in the functionality and clinical symptomatology of patients.•Prolactin levels mediated negative symptomatology and functional outcomes in males.•Prolactin was associated with functioning and diminished expression in males.•Prolactin was associated with working memory in females.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Female</subject><subject>First-episode psychosis</subject><subject>Functioning</subject><subject>Humans</subject><subject>Hyperprolactinemia - blood</subject><subject>Male</subject><subject>Negative symptoms</subject><subject>Prolactin</subject><subject>Prolactin - blood</subject><subject>Psychotic Disorders - blood</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Sex Characteristics</subject><subject>Sex Factors</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0306-4530</issn><issn>1873-3360</issn><issn>1873-3360</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMlOwzAQQC0EgrL8AvKRS4q3uM4NhNgkJA7A2XLHE9VVmhTbYfl7XLVw5TSj0ZvtEXLO2ZQzri-X03X67nHEfiqYUKU441zskQk3M1lJqdk-mTDJdKVqyY7IcUpLxpg2WhySI9lwpmsjJsS_4Bf1oW0xYg-YaOjpOg6dg1yyDj-wS9T1nkIX-gCuo8OYYVjtSJcD9jnRz5AX1NE2xJRpuQwWQw5AcR3S4PGUHLSuS3i2iyfk7e729eahenq-f7y5fqpAqDpXUjct55LVbc0dtMJIDY2RwikOYIw0Wgmm9ExzX2uvldS10sobJ30j5grkCbnYzi0fvI-Ysl2FBNh1rsdhTFYy05hZmcgLqrcoxCGliK1dx7By8dtyZjeG7dL-GrYbw3ZruDSe73aM8xX6v7ZfpQW42gLFHH4EjDZB2Lj1ISJk64fw344fKSKQKQ</recordid><startdate>202411</startdate><enddate>202411</enddate><creator>Jordà-Baleri, Teresa</creator><creator>Garriga, Marina</creator><creator>Mezquida, Gisela</creator><creator>Cuesta, Manuel J.</creator><creator>Martinez-Aran, Anabel</creator><creator>Garcia-Rizo, Clemente</creator><creator>Lobo, Antonio</creator><creator>González-Pinto, Ana</creator><creator>Diaz-Caneja, Covadonga M.</creator><creator>Roldán, Alexandra</creator><creator>Vieta, Eduard</creator><creator>Baeza, Inmaculada</creator><creator>Trabsa, Amira</creator><creator>Montalvo, Itziar</creator><creator>Tortorella, Alfonso</creator><creator>Menculini, Giulia</creator><creator>Verdolini, Norma</creator><creator>Ramos-Quiroga, Josep Antoni</creator><creator>Sánchez Torres, Ana M.</creator><creator>Bernardo, Miquel</creator><creator>Amoretti, Silvia</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202411</creationdate><title>Sex differences in prolactin levels and clinical outcomes in patients with a first psychotic episode</title><author>Jordà-Baleri, Teresa ; Garriga, Marina ; Mezquida, Gisela ; Cuesta, Manuel J. ; Martinez-Aran, Anabel ; Garcia-Rizo, Clemente ; Lobo, Antonio ; González-Pinto, Ana ; Diaz-Caneja, Covadonga M. ; Roldán, Alexandra ; Vieta, Eduard ; Baeza, Inmaculada ; Trabsa, Amira ; Montalvo, Itziar ; Tortorella, Alfonso ; Menculini, Giulia ; Verdolini, Norma ; Ramos-Quiroga, Josep Antoni ; Sánchez Torres, Ana M. ; Bernardo, Miquel ; Amoretti, Silvia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c245t-369f11305f51acf2836c9832a41cc8838642046761d56d64365464d8a3d92b4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Female</topic><topic>First-episode psychosis</topic><topic>Functioning</topic><topic>Humans</topic><topic>Hyperprolactinemia - blood</topic><topic>Male</topic><topic>Negative symptoms</topic><topic>Prolactin</topic><topic>Prolactin - blood</topic><topic>Psychotic Disorders - blood</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Sex Characteristics</topic><topic>Sex Factors</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jordà-Baleri, Teresa</creatorcontrib><creatorcontrib>Garriga, Marina</creatorcontrib><creatorcontrib>Mezquida, Gisela</creatorcontrib><creatorcontrib>Cuesta, Manuel J.</creatorcontrib><creatorcontrib>Martinez-Aran, Anabel</creatorcontrib><creatorcontrib>Garcia-Rizo, Clemente</creatorcontrib><creatorcontrib>Lobo, Antonio</creatorcontrib><creatorcontrib>González-Pinto, Ana</creatorcontrib><creatorcontrib>Diaz-Caneja, Covadonga M.</creatorcontrib><creatorcontrib>Roldán, Alexandra</creatorcontrib><creatorcontrib>Vieta, Eduard</creatorcontrib><creatorcontrib>Baeza, Inmaculada</creatorcontrib><creatorcontrib>Trabsa, Amira</creatorcontrib><creatorcontrib>Montalvo, Itziar</creatorcontrib><creatorcontrib>Tortorella, Alfonso</creatorcontrib><creatorcontrib>Menculini, Giulia</creatorcontrib><creatorcontrib>Verdolini, Norma</creatorcontrib><creatorcontrib>Ramos-Quiroga, Josep Antoni</creatorcontrib><creatorcontrib>Sánchez Torres, Ana M.</creatorcontrib><creatorcontrib>Bernardo, Miquel</creatorcontrib><creatorcontrib>Amoretti, Silvia</creatorcontrib><creatorcontrib>PEPs Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Psychoneuroendocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jordà-Baleri, Teresa</au><au>Garriga, Marina</au><au>Mezquida, Gisela</au><au>Cuesta, Manuel J.</au><au>Martinez-Aran, Anabel</au><au>Garcia-Rizo, Clemente</au><au>Lobo, Antonio</au><au>González-Pinto, Ana</au><au>Diaz-Caneja, Covadonga M.</au><au>Roldán, Alexandra</au><au>Vieta, Eduard</au><au>Baeza, Inmaculada</au><au>Trabsa, Amira</au><au>Montalvo, Itziar</au><au>Tortorella, Alfonso</au><au>Menculini, Giulia</au><au>Verdolini, Norma</au><au>Ramos-Quiroga, Josep Antoni</au><au>Sánchez Torres, Ana M.</au><au>Bernardo, Miquel</au><au>Amoretti, Silvia</au><aucorp>PEPs Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sex differences in prolactin levels and clinical outcomes in patients with a first psychotic episode</atitle><jtitle>Psychoneuroendocrinology</jtitle><addtitle>Psychoneuroendocrinology</addtitle><date>2024-11</date><risdate>2024</risdate><volume>169</volume><spage>107112</spage><pages>107112-</pages><artnum>107112</artnum><issn>0306-4530</issn><issn>1873-3360</issn><eissn>1873-3360</eissn><abstract>To analyze the clinical, neurocognitive, and functional impact of prolactin levels according to sex in patients with a First Episode Psychosis (FEP).
We measured prolactin levels in 221 non-affective FEP patients treated with antipsychotics (AP) and 224 healthy controls, at baseline and 2-year follow-up. We examined whether the relationships between clinical and functional variables were mediated by prolactin, controlling for antipsychotic use, according to sex.
Prolactin levels were higher in patients when compared to controls at both time points. Baseline factors associated with prolactin were chlorpromazine equivalents, attention, and executive functioning. In the FEP group, prolactin levels were associated with functioning and diminished expression in males, and with working memory in females. Prolactin levels (p=0.0134) played a role as a mediator between negative symptomatology (p=0.086) and functional outcome (p=0.008) only in FEP male patients at baseline.
Prolactin plays a role in the functionality and clinical symptomatology of FEP patients. Our results suggest that pharmacological counselling in patients with hyperprolactinemia at baseline and negative symptomatology might improve their functional and clinical outcomes.
•Prolactin plays a role in the functionality and clinical symptomatology of patients.•Prolactin levels mediated negative symptomatology and functional outcomes in males.•Prolactin was associated with functioning and diminished expression in males.•Prolactin was associated with working memory in females.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>39106582</pmid><doi>10.1016/j.psyneuen.2024.107112</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-4530 |
| ispartof | Psychoneuroendocrinology, 2024-11, Vol.169, p.107112, Article 107112 |
| issn | 0306-4530 1873-3360 1873-3360 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3089878321 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adolescent Adult Antipsychotic Agents - therapeutic use Female First-episode psychosis Functioning Humans Hyperprolactinemia - blood Male Negative symptoms Prolactin Prolactin - blood Psychotic Disorders - blood Psychotic Disorders - drug therapy Sex Characteristics Sex Factors Treatment Outcome Young Adult |
| title | Sex differences in prolactin levels and clinical outcomes in patients with a first psychotic episode |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T11%3A13%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sex%20differences%20in%20prolactin%20levels%20and%20clinical%20outcomes%20in%20patients%20with%20a%20first%20psychotic%20episode&rft.jtitle=Psychoneuroendocrinology&rft.au=Jord%C3%A0-Baleri,%20Teresa&rft.aucorp=PEPs%20Group&rft.date=2024-11&rft.volume=169&rft.spage=107112&rft.pages=107112-&rft.artnum=107112&rft.issn=0306-4530&rft.eissn=1873-3360&rft_id=info:doi/10.1016/j.psyneuen.2024.107112&rft_dat=%3Cproquest_cross%3E3089878321%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3089878321&rft_id=info:pmid/39106582&rft_els_id=S0306453024001562&rfr_iscdi=true |